
    
      This is a phase I, randomized, blinded study to evaluate the safety, tolerability,
      pharmacokinetics and immunogenicity of MEDI0382 following single dose administration to
      overweight/obese but otherwise healthy adult male and female subjects of Japanese or Chinese
      descent
    
  